Back grey_arrow_rt.gif
 
 
GEOVAX LABS GRANTED ALLOWANCE BY FDA TO START PHASE 1 CLINICAL TRIAL FOR HIV/AIDS THERAPEUTIC VACCINE - attached press release
 
 
  Download the PDF here
 
Company Will Begin Non-Blinded Study in HIV Infected Individuals Who Started Drug Treatment During Their First Year of Infection
 
GeoVax Labs, Inc. (OTCBB: GOVX), a biotechnology company that creates, develops, and tests innovative HIV/AIDS vaccines, is now allowed by the FDA (US Food and Drug Administration) to begin a phase 1 clinical trial for GeoVax's therapeutic vaccine, which is intended as a treatment for individuals infected with HIV (Human Immunodeficiency Virus). The company will begin a non-blinded study in HIV infected individuals who started drug treatment during their first year of infection. An unmet need exists in the market for a HIV therapeutic vaccine if it can reduce the need for expensive and poorly tolerated lifelong oral medications currently available to infected individuals.
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org